To see if Gene-Eden-VIR/Novirin clears the human papillomavirus (HPV), Dr. Hanan Polansky, Dr. Edan Itzkovitz, and Adrian Javaherian, from the Center for the Biology of Chronic Disease (CBCD), conducted a clinical study. The study followed FDA guidelines.

The treatment included 1, 2, 3, or 4 capsules of Gene-Eden-VIR/Novirin per day.  Each capsule includes 100 mg of a quercetin extract, 150 mg of a green tea extract, 50 mg of a cinnamon extract, 25 mg of a licorice extract, and 100 mcg of selenium.  The treatment lasted between 2 to 12 months.  The study included 59 participants, 19 male and 30 female, all suffering from a symptomatic HPV infection.  The ages were 20 to 80 years old, with an average of 47 years old. 27 participants had genital warts, 4, oral warts, 12 cutaneous warts, 3 bleeding after sexual intercourse, 4 vaginal bleeding between periods, 6 a sensation of fullness in the pelvis, 3 anus or rectal bleeding, and 16 a genital itching sensation.

The study showed that the participants who took Gene-Eden-VIR/Novirin cleared the virus much faster than the untreated individuals in the five control groups.  Most remarkably, the results showed that after 12 months of treatment 100% of the treated participants cleared the virus.  In contrast, only 53%, 52% 65%, 20% and 77% of the untreated individuals in the five control groups cleared the virus.  All other untreated individuals did not clear the virus!  In regard to safety, the study showed that the herbal Gene-Eden-VIR/Novirin caused no side effects.

To conclude, the study “showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time to HPV clearance, increased the percentage of HPV-free individuals, and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category.” 

The study was published in the medical journal Drug Design, Development and Therapy, Volume 2017:11 Pages 575-583.

In the following video, Dr. Hanan Polansky and Dr. Edan Itzkovitz explain their study.